ARTICLE | Company News
EntreMed, Selected Value Therapeutics I LLC deal
September 20, 2010 7:00 AM UTC
EntreMed granted Selected Value Therapeutics I an option to license rights to develop and commercialize ENMD-2076 in China and Taiwan. The inhibitor of aurora kinase A ( AURKA; Aurora-A) and multip...